Did AI‑Driven Obesity Research Wins and Strong 2025 Results Just Shift IQVIA's (IQV) Investment Narrative?

2026-03-09 23:56:03

Abstract generation in progress

IQVIA Holdings reported strong 2025 results with near double-digit revenue and EPS growth, and robust R&D Solutions net bookings. Concurrently, a collaboration with the Duke Clinical Research Institute for obesity research highlights IQVIA’s AI and real-world evidence capabilities, potentially strengthening its backlog-driven growth story. Despite these positive developments, the company’s high debt levels and competitive pricing pressures remain key investment risks.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.